FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2097405564> ?p ?o ?g. }

• W2097405564 endingPage "725" @default.
• W2097405564 startingPage "714" @default.
• W2097405564 abstract "The combination of daclatasvir, a hepatitis C virus (HCV) NS5A inhibitor, and the NS5B inhibitor sofosbuvir has shown efficacy in patients with HCV monoinfection. Data are lacking on the efficacy and safety of this combination in patients coinfected with human immunodeficiency virus type 1 (HIV-1).This was an open-label study involving 151 patients who had not received HCV treatment and 52 previously treated patients, all of whom were coinfected with HIV-1. Previously untreated patients were randomly assigned in a 2:1 ratio to receive either 12 weeks or 8 weeks of daclatasvir at a standard dose of 60 mg daily (with dose adjustment for concomitant antiretroviral medications) plus 400 mg of sofosbuvir daily. Previously treated patients were assigned to undergo 12 weeks of therapy at the same doses. The primary end point was a sustained virologic response at week 12 after the end of therapy among previously untreated patients with HCV genotype 1 who were treated for 12 weeks.Patients had HCV genotypes 1 through 4 (83% with genotype 1), and 14% had compensated cirrhosis; 98% were receiving antiretroviral therapy. Among patients with genotype 1, a sustained virologic response was reported in 96.4% (95% confidence interval [CI], 89.8 to 99.2) who were treated for 12 weeks and in 75.6% (95% CI, 59.7 to 87.6) who were treated for 8 weeks among previously untreated patients and in 97.7% (95% CI, 88.0 to 99.9) who were treated for 12 weeks among previously treated patients. Rates of sustained virologic response across all genotypes were 97.0% (95% CI, 91.6 to 99.4), 76.0% (95% CI, 61.8 to 86.9), and 98.1% (95% CI, 89.7 to 100), respectively. The most common adverse events were fatigue, nausea, and headache. There were no study-drug discontinuations because of adverse events. HIV-1 suppression was not compromised.Among previously untreated HIV-HCV coinfected patients receiving daclatasvir plus sofosbuvir for HCV infection, the rate of sustained virologic response across all genotypes was 97.0% after 12 weeks of treatment and 76.0% after 8 weeks. (Funded by Bristol-Myers Squibb; ALLY-2 ClinicalTrials.gov number, NCT02032888.)." @default.
• W2097405564 created "2016-06-24" @default.
• W2097405564 creator A5002362140 @default.
• W2097405564 creator A5004741643 @default.
• W2097405564 creator A5006160300 @default.
• W2097405564 creator A5009797362 @default.
• W2097405564 creator A5009847961 @default.
• W2097405564 creator A5010850224 @default.
• W2097405564 creator A5013736817 @default.
• W2097405564 creator A5016364925 @default.
• W2097405564 creator A5021117477 @default.
• W2097405564 creator A5023109452 @default.
• W2097405564 creator A5024836953 @default.
• W2097405564 creator A5026282992 @default.
• W2097405564 creator A5028514368 @default.
• W2097405564 creator A5038328394 @default.
• W2097405564 creator A5041570571 @default.
• W2097405564 creator A5054201295 @default.
• W2097405564 creator A5055495178 @default.
• W2097405564 creator A5069170911 @default.
• W2097405564 creator A5069241202 @default.
• W2097405564 creator A5069780528 @default.
• W2097405564 creator A5077980742 @default.
• W2097405564 creator A5081795781 @default.
• W2097405564 creator A5083277958 @default.
• W2097405564 creator A5083359170 @default.
• W2097405564 creator A5085632354 @default.
• W2097405564 creator A5087714251 @default.
• W2097405564 creator A5089993955 @default.
• W2097405564 date "2015-08-20" @default.
• W2097405564 modified "2023-09-29" @default.
• W2097405564 title "Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1" @default.
• W2097405564 cites W1540111651 @default.
• W2097405564 cites W1963623224 @default.
• W2097405564 cites W1972821220 @default.
• W2097405564 cites W1980771473 @default.
• W2097405564 cites W1992668008 @default.
• W2097405564 cites W1993484328 @default.
• W2097405564 cites W1996434966 @default.
• W2097405564 cites W2001634163 @default.
• W2097405564 cites W2030470608 @default.
• W2097405564 cites W2031859820 @default.
• W2097405564 cites W2035804055 @default.
• W2097405564 cites W2047156711 @default.
• W2097405564 cites W2062563125 @default.
• W2097405564 cites W2081897332 @default.
• W2097405564 cites W2092646281 @default.
• W2097405564 cites W2104103604 @default.
• W2097405564 cites W2106081736 @default.
• W2097405564 cites W2113428683 @default.
• W2097405564 cites W2118684050 @default.
• W2097405564 cites W2121595515 @default.
• W2097405564 cites W2124892937 @default.
• W2097405564 cites W2151554611 @default.
• W2097405564 cites W2152282081 @default.
• W2097405564 cites W2153783362 @default.
• W2097405564 cites W2154574897 @default.
• W2097405564 cites W2161578383 @default.
• W2097405564 cites W2164466220 @default.
• W2097405564 cites W2166962970 @default.
• W2097405564 cites W2320342518 @default.
• W2097405564 cites W2323354293 @default.
• W2097405564 cites W83931366 @default.
• W2097405564 doi "https://doi.org/10.1056/nejmoa1503153" @default.
• W2097405564 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26196502" @default.
• W2097405564 hasPublicationYear "2015" @default.
• W2097405564 type Work @default.
• W2097405564 sameAs 2097405564 @default.
• W2097405564 citedByCount "372" @default.
• W2097405564 countsByYear W20974055642015 @default.
• W2097405564 countsByYear W20974055642016 @default.
• W2097405564 countsByYear W20974055642017 @default.
• W2097405564 countsByYear W20974055642018 @default.
• W2097405564 countsByYear W20974055642019 @default.
• W2097405564 countsByYear W20974055642020 @default.
• W2097405564 countsByYear W20974055642021 @default.
• W2097405564 countsByYear W20974055642022 @default.
• W2097405564 countsByYear W20974055642023 @default.
• W2097405564 crossrefType "journal-article" @default.
• W2097405564 hasAuthorship W2097405564A5002362140 @default.
• W2097405564 hasAuthorship W2097405564A5004741643 @default.
• W2097405564 hasAuthorship W2097405564A5006160300 @default.
• W2097405564 hasAuthorship W2097405564A5009797362 @default.
• W2097405564 hasAuthorship W2097405564A5009847961 @default.
• W2097405564 hasAuthorship W2097405564A5010850224 @default.
• W2097405564 hasAuthorship W2097405564A5013736817 @default.
• W2097405564 hasAuthorship W2097405564A5016364925 @default.
• W2097405564 hasAuthorship W2097405564A5021117477 @default.
• W2097405564 hasAuthorship W2097405564A5023109452 @default.
• W2097405564 hasAuthorship W2097405564A5024836953 @default.
• W2097405564 hasAuthorship W2097405564A5026282992 @default.
• W2097405564 hasAuthorship W2097405564A5028514368 @default.
• W2097405564 hasAuthorship W2097405564A5038328394 @default.
• W2097405564 hasAuthorship W2097405564A5041570571 @default.
• W2097405564 hasAuthorship W2097405564A5054201295 @default.
• W2097405564 hasAuthorship W2097405564A5055495178 @default.
• W2097405564 hasAuthorship W2097405564A5069170911 @default.
• W2097405564 hasAuthorship W2097405564A5069241202 @default.

• next